Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Celularity Inc (CELU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: CELU (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.5
1 Year Target Price $2.5
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.01% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.53M USD | Price to earnings Ratio - | 1Y Target Price 2.5 |
Price to earnings Ratio - | 1Y Target Price 2.5 | ||
Volume (30-day avg) 1 | Beta 0.76 | 52 Weeks Range 1.00 - 4.34 | Updated Date 07/14/2025 |
52 Weeks Range 1.00 - 4.34 | Updated Date 07/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -106.77% | Operating Margin (TTM) -52.25% |
Management Effectiveness
Return on Assets (TTM) -17.42% | Return on Equity (TTM) -232.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 118630873 | Price to Sales(TTM) 0.93 |
Enterprise Value 118630873 | Price to Sales(TTM) 0.93 | ||
Enterprise Value to Revenue 2.19 | Enterprise Value to EBITDA -36.78 | Shares Outstanding 23949200 | Shares Floating 11684589 |
Shares Outstanding 23949200 | Shares Floating 11684589 | ||
Percent Insiders 51.26 | Percent Institutions 14.66 |
Upturn AI SWOT
Celularity Inc
Company Overview
History and Background
Celularity Inc. was founded in 2016, emerging from Celgene's placental-derived assets. It focuses on developing allogeneic cell therapies for cancer and immune diseases. Celularity went public through a SPAC merger in 2021.
Core Business Areas
- Cellular Medicine: Development of off-the-shelf allogeneic cell therapies derived from the placenta to treat various diseases including hematologic cancers, solid tumors, and autoimmune disorders.
- Biomanufacturing: Proprietary manufacturing processes and infrastructure for the efficient production and scale-up of cell therapies.
Leadership and Structure
Robert J. Hariri, M.D., Ph.D., is the Founder, Chairman, and CEO. The company has a typical organizational structure for a biotechnology company, with departments for research, development, manufacturing, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- CYNK-001: An allogeneic natural killer (NK) cell therapy targeting hematologic cancers and solid tumors. It is currently in clinical trials. Market share data not publicly available. Competitors include Nkarta (NKTX), Fate Therapeutics (FATE), and Gamida Cell (GMDA).
- CYTO-100: An allogeneic placental derived mesenchymal-like adherent stromal cell (hMSC) therapy that promotes tissue repair, reduces inflammation and modulates the immune response. Currently in clinical trials. Market share data not publicly available. Competitors include Mesoblast (MESO) and Vericel Corporation (VCEL).
Market Dynamics
Industry Overview
The cell therapy industry is rapidly growing, driven by advancements in biotechnology and increasing demand for novel cancer and immune disease treatments. There is significant competition and high regulatory hurdles.
Positioning
Celularity aims to be a leader in allogeneic cell therapies, leveraging its placental-derived technology and manufacturing capabilities. Its competitive advantage lies in scalable 'off-the-shelf' cell therapies.
Total Addressable Market (TAM)
The TAM for cell therapies is estimated to reach billions of dollars, expected to continue to grow significantly over the next decade. Celularity is positioned to capture a portion of this market with its allogeneic cell therapy platform.
Upturn SWOT Analysis
Strengths
- Proprietary placental-derived cell therapy platform
- Scalable allogeneic cell therapy manufacturing
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Limited commercialized products
- Reliance on clinical trial success
- Significant cash burn
- Relatively small market capitalization compared to larger biotech companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to new indications
- Positive clinical trial results
- Regulatory approvals for lead product candidates
Threats
- Clinical trial failures
- Competition from other cell therapy companies
- Regulatory setbacks
- Financial constraints
Competitors and Market Share
Key Competitors
- NKTX
- FATE
- MESO
- VCEL
- GMDA
Competitive Landscape
Celularity competes in a highly competitive cell therapy market. Its advantage is based on placental-derived cell therapies, while its disadvantage lies in its relatively small size and limited resources compared to larger competitors.
Major Acquisitions
Neostem
- Year: 2018
- Acquisition Price (USD millions): 60
- Strategic Rationale: Expanded cell therapy portfolio and manufacturing capabilities.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been driven by expanding the pipeline of cell therapy candidates and initiating clinical trials.
Future Projections: Future growth is dependent on clinical trial success and potential regulatory approvals. Analyst estimates vary widely due to the high-risk nature of drug development.
Recent Initiatives: Recent initiatives include advancing lead product candidates (CYNK-001 and CYTO-100) through clinical trials and expanding manufacturing capabilities.
Summary
Celularity is a high-risk, high-reward biotechnology company focused on cell therapies. Its placental-derived technology is promising, but its success depends on clinical trial outcomes and securing regulatory approvals. Significant cash burn and competition are key challenges that need to be looked out for. Successfully navigating these challenges will determine Celularity's long-term viability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K, 10-Q)
- Company Website
- Analyst Reports
- Press Releases
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share estimates are approximate and may not reflect actual market conditions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celularity Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2019-08-08 | Founder, CEO & Chairman Dr. Robert Joseph Hariri M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://www.celularity.com |
Full time employees 123 | Website https://www.celularity.com | ||
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.